This study enrolled adults aged 18 years or older who were diagnosed with obesity, defined either through diagnostic codes E66.0 and E66.9 or a Body Mass Index (BMI) of 30 or above, and who had 2 medical encounters related to this diagnosis in the database
Obesity, defined as a body mass index above 30 kg/m 2 , is also increasingly prevalent worldwide and has become a challenge to the various healthcare systems and societies
Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes
These can include nausea, diarrhea, vomiting, constipation, and decreased appetite
When patients arrive at a telehealth site already requesting a GLP-1 drug, the marketing funnel shortens considerably
For comparison, transdermal medications that work well (like nicotine patches) involve molecules smaller than 500 daltons